FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 730 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Inavolisib June 26, 2025 Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... December 12, 2025 Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... December 4, 2020 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Load more HOT NEWS Health inequalities: breaking down barriers to cancer screening For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored Teacher Reads To Students One Day After Having Brain Surgery Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in...
